Analysis	B:C0936012
of	O
patients	O
with	O
diabetes	O
and	O
complicated	O
intra-abdominal	O
infection	I:C1112209
or	O
complicated	O
urinary	O
tract	I:C0042029
infection	I:C0042029
in	O
phase	O
3	I:C0282461
trials	I:C0282461
of	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
.	O

Analysis	O
of	O
patients	O
with	O
diabetes	B:C0011847
and	O
complicated	O
intra-abdominal	O
infection	I:C1112209
or	O
complicated	O
urinary	O
tract	I:C0042029
infection	I:C0042029
in	O
phase	O
3	I:C0282461
trials	I:C0282461
of	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
.	O

Analysis	O
of	O
patients	O
with	O
diabetes	O
and	O
complicated	O
intra-abdominal	B:C1112209
infection	I:C1112209
or	O
complicated	O
urinary	O
tract	I:C0042029
infection	I:C0042029
in	O
phase	O
3	I:C0282461
trials	I:C0282461
of	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
.	O

Analysis	O
of	O
patients	O
with	O
diabetes	O
and	O
complicated	O
intra-abdominal	O
infection	I:C1112209
or	O
complicated	O
urinary	B:C0042029
tract	I:C0042029
infection	I:C0042029
in	O
phase	O
3	I:C0282461
trials	I:C0282461
of	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
.	O

Analysis	O
of	O
patients	O
with	O
diabetes	O
and	O
complicated	O
intra-abdominal	O
infection	I:C1112209
or	O
complicated	O
urinary	O
tract	I:C0042029
infection	I:C0042029
in	O
phase	B:C0282461
3	I:C0282461
trials	I:C0282461
of	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
.	O

Analysis	O
of	O
patients	O
with	O
diabetes	O
and	O
complicated	O
intra-abdominal	O
infection	I:C1112209
or	O
complicated	O
urinary	O
tract	I:C0042029
infection	I:C0042029
in	O
phase	O
3	I:C0282461
trials	I:C0282461
of	O
ceftolozane	B:C3656593
/	I:C3656593
tazobactam	I:C3656593
.	O

Diabetes	B:C0011849
mellitus	I:C0011849
and	O
hyperglycemia	O
are	O
associated	O
with	O
increased	O
susceptibility	I:C2748958
to	I:C2748958
bacterial	I:C2748958
infections	I:C2748958
and	O
poor	O
treatment	O
outcomes	O
.	O

Diabetes	O
mellitus	I:C0011849
and	O
hyperglycemia	B:C0020456
are	O
associated	O
with	O
increased	O
susceptibility	I:C2748958
to	I:C2748958
bacterial	I:C2748958
infections	I:C2748958
and	O
poor	O
treatment	O
outcomes	O
.	O

Diabetes	O
mellitus	I:C0011849
and	O
hyperglycemia	O
are	O
associated	O
with	O
increased	B:C2748958
susceptibility	I:C2748958
to	I:C2748958
bacterial	I:C2748958
infections	I:C2748958
and	O
poor	O
treatment	O
outcomes	O
.	O

This	O
post	B:C0220825
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	I:C1112209
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	O
tract	I:C0042029
infections	I:C0042029
(	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

This	O
post	O
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	B:C0087111
of	O
complicated	O
intra-abdominal	O
infections	I:C1112209
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	O
tract	I:C0042029
infections	I:C0042029
(	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

This	O
post	O
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	B:C1112209
infections	I:C1112209
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	O
tract	I:C0042029
infections	I:C0042029
(	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

This	O
post	O
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	I:C1112209
(	O
complicated	B:C1112209
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	O
tract	I:C0042029
infections	I:C0042029
(	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

This	O
post	O
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	I:C1112209
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	B:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

This	O
post	O
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	I:C1112209
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	O
tract	I:C0042029
infections	I:C0042029
(	O
complicated	B:C0042029
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

This	O
post	O
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	I:C1112209
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	O
tract	I:C0042029
infections	I:C0042029
(	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	B:C0220825
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

This	O
post	O
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	I:C1112209
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	O
tract	I:C0042029
infections	I:C0042029
(	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	B:C0011847
treated	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

This	O
post	O
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	I:C1112209
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	O
tract	I:C0042029
infections	I:C0042029
(	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	B:C0087111
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

This	O
post	O
hoc	I:C0220825
evaluation	I:C0220825
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	I:C1112209
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
)	O
and	O
complicated	O
urinary	O
tract	I:C0042029
infections	I:C0042029
(	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane	B:C3656593
/	I:C3656593
tazobactam	I:C3656593
and	O
comparators	O
.	O

Ceftolozane	B:C3656593
/	I:C3656593
tazobactam	I:C3656593
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram	O
-	I:C0018150
negative	I:C0018150
pathogens	I:C0018150
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
(	O
with	O
metronidazole	O
)	O
and	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
including	O
pyelonephritis	O
)	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
is	O
an	O
antibacterial	B:C0279516
with	O
potent	O
activity	O
against	O
Gram	O
-	I:C0018150
negative	I:C0018150
pathogens	I:C0018150
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
(	O
with	O
metronidazole	O
)	O
and	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
including	O
pyelonephritis	O
)	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram	B:C0018150
-	I:C0018150
negative	I:C0018150
pathogens	I:C0018150
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
(	O
with	O
metronidazole	O
)	O
and	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
including	O
pyelonephritis	O
)	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram	O
-	I:C0018150
negative	I:C0018150
pathogens	I:C0018150
and	O
is	O
approved	O
for	O
the	O
treatment	B:C0087111
of	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
(	O
with	O
metronidazole	O
)	O
and	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
including	O
pyelonephritis	O
)	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram	O
-	I:C0018150
negative	I:C0018150
pathogens	I:C0018150
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
complicated	B:C1112209
intra-abdominal	I:C1112209
infections	I:C1112209
(	O
with	O
metronidazole	O
)	O
and	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
including	O
pyelonephritis	O
)	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram	O
-	I:C0018150
negative	I:C0018150
pathogens	I:C0018150
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
(	O
with	O
metronidazole	B:C0025872
)	O
and	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
including	O
pyelonephritis	O
)	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram	O
-	I:C0018150
negative	I:C0018150
pathogens	I:C0018150
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
(	O
with	O
metronidazole	O
)	O
and	O
complicated	B:C0042029
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
including	O
pyelonephritis	O
)	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram	O
-	I:C0018150
negative	I:C0018150
pathogens	I:C0018150
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
(	O
with	O
metronidazole	O
)	O
and	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
including	O
pyelonephritis	B:C0034186
)	O
.	O

Patients	O
from	O
the	O
phase	B:C0282461
3	I:C0282461
ASPECT	I:C0282461
studies	O
with	O
(	O
n	O
=	O
245	O
)	O
and	O
without	O
(	O
n	O
=	O
1802	O
)	O
diabetes	O
were	O
compared	O
to	O
evaluate	O
the	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
of	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparators	O
.	O

Patients	O
from	O
the	O
phase	O
3	I:C0282461
ASPECT	I:C0282461
studies	B:C2603343
with	O
(	O
n	O
=	O
245	O
)	O
and	O
without	O
(	O
n	O
=	O
1802	O
)	O
diabetes	O
were	O
compared	O
to	O
evaluate	O
the	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
of	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparators	O
.	O

Patients	O
from	O
the	O
phase	O
3	I:C0282461
ASPECT	I:C0282461
studies	O
with	O
(	O
n	O
=	O
245	O
)	O
and	O
without	O
(	O
n	O
=	O
1802	O
)	O
diabetes	B:C0011847
were	O
compared	O
to	O
evaluate	O
the	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
of	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparators	O
.	O

Patients	O
from	O
the	O
phase	O
3	I:C0282461
ASPECT	I:C0282461
studies	O
with	O
(	O
n	O
=	O
245	O
)	O
and	O
without	O
(	O
n	O
=	O
1802	O
)	O
diabetes	O
were	O
compared	O
to	O
evaluate	B:C0220825
the	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
of	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparators	O
.	O

Patients	O
from	O
the	O
phase	O
3	I:C0282461
ASPECT	I:C0282461
studies	O
with	O
(	O
n	O
=	O
245	O
)	O
and	O
without	O
(	O
n	O
=	O
1802	O
)	O
diabetes	O
were	O
compared	O
to	O
evaluate	O
the	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
of	O
ceftolozane	B:C3656593
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparators	O
.	O

Significantly	O
more	O
patients	O
with	O
than	O
without	O
diabetes	B:C0011847
were	O
65	O
years	O
of	O
age	O
or	O
older	O
;	O
patients	O
with	O
diabetes	O
were	O
also	O
more	O
likely	O
to	O
weigh	O
≥	O
75	O
kg	O
at	O
baseline	O
(	O
57.1	O
%	O
vs	O
44.5	O
%	O
)	O
,	O
to	O
have	O
renal	O
impairment	I:C1565489
(	O
48.5	O
%	O
vs	O
30.2	O
%	O
)	O
,	O
or	O
to	O
have	O
APACHE	O
II	I:C0489438
scores	I:C0489438
≥	O
10	O
(	O
33.8	O
%	O
vs	O
17.0	O
%	O
)	O
.	O

Significantly	O
more	O
patients	O
with	O
than	O
without	O
diabetes	O
were	O
65	O
years	O
of	O
age	O
or	O
older	B:C0001792
;	O
patients	O
with	O
diabetes	O
were	O
also	O
more	O
likely	O
to	O
weigh	O
≥	O
75	O
kg	O
at	O
baseline	O
(	O
57.1	O
%	O
vs	O
44.5	O
%	O
)	O
,	O
to	O
have	O
renal	O
impairment	I:C1565489
(	O
48.5	O
%	O
vs	O
30.2	O
%	O
)	O
,	O
or	O
to	O
have	O
APACHE	O
II	I:C0489438
scores	I:C0489438
≥	O
10	O
(	O
33.8	O
%	O
vs	O
17.0	O
%	O
)	O
.	O

Significantly	O
more	O
patients	O
with	O
than	O
without	O
diabetes	O
were	O
65	O
years	O
of	O
age	O
or	O
older	O
;	O
patients	O
with	O
diabetes	B:C0011847
were	O
also	O
more	O
likely	O
to	O
weigh	O
≥	O
75	O
kg	O
at	O
baseline	O
(	O
57.1	O
%	O
vs	O
44.5	O
%	O
)	O
,	O
to	O
have	O
renal	O
impairment	I:C1565489
(	O
48.5	O
%	O
vs	O
30.2	O
%	O
)	O
,	O
or	O
to	O
have	O
APACHE	O
II	I:C0489438
scores	I:C0489438
≥	O
10	O
(	O
33.8	O
%	O
vs	O
17.0	O
%	O
)	O
.	O

Significantly	O
more	O
patients	O
with	O
than	O
without	O
diabetes	O
were	O
65	O
years	O
of	O
age	O
or	O
older	O
;	O
patients	O
with	O
diabetes	O
were	O
also	O
more	O
likely	O
to	O
weigh	O
≥	O
75	O
kg	O
at	O
baseline	O
(	O
57.1	O
%	O
vs	O
44.5	O
%	O
)	O
,	O
to	O
have	O
renal	B:C1565489
impairment	I:C1565489
(	O
48.5	O
%	O
vs	O
30.2	O
%	O
)	O
,	O
or	O
to	O
have	O
APACHE	O
II	I:C0489438
scores	I:C0489438
≥	O
10	O
(	O
33.8	O
%	O
vs	O
17.0	O
%	O
)	O
.	O

Significantly	O
more	O
patients	O
with	O
than	O
without	O
diabetes	O
were	O
65	O
years	O
of	O
age	O
or	O
older	O
;	O
patients	O
with	O
diabetes	O
were	O
also	O
more	O
likely	O
to	O
weigh	O
≥	O
75	O
kg	O
at	O
baseline	O
(	O
57.1	O
%	O
vs	O
44.5	O
%	O
)	O
,	O
to	O
have	O
renal	O
impairment	I:C1565489
(	O
48.5	O
%	O
vs	O
30.2	O
%	O
)	O
,	O
or	O
to	O
have	O
APACHE	B:C0489438
II	I:C0489438
scores	I:C0489438
≥	O
10	O
(	O
33.8	O
%	O
vs	O
17.0	O
%	O
)	O
.	O

More	O
patients	O
with	O
diabetes	B:C0011847
had	O
comorbidities	O
and	O
an	O
increased	O
incidence	O
of	O
complicating	O
factors	O
in	O
both	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
.	O

More	O
patients	O
with	O
diabetes	O
had	O
comorbidities	O
and	O
an	O
increased	O
incidence	O
of	O
complicating	O
factors	O
in	O
both	O
complicated	B:C1112209
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
.	O

More	O
patients	O
with	O
diabetes	O
had	O
comorbidities	O
and	O
an	O
increased	O
incidence	O
of	O
complicating	O
factors	O
in	O
both	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
complicated	B:C0042029
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
.	O

Clinical	O
complicated	B:C1112209
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
composite	O
cure	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
rates	O
across	O
study	O
treatments	I:C3161471
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

Clinical	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
composite	O
cure	O
complicated	B:C0042029
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
rates	O
across	O
study	O
treatments	I:C3161471
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

Clinical	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
composite	O
cure	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
rates	O
across	O
study	B:C3161471
treatments	I:C3161471
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

Clinical	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
composite	O
cure	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
rates	O
across	O
study	O
treatments	I:C3161471
were	O
lower	B:C0441994
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

Clinical	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
composite	O
cure	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
rates	O
across	O
study	O
treatments	I:C3161471
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	B:C0011847
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

Clinical	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
composite	O
cure	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
rates	O
across	O
study	O
treatments	I:C3161471
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
complicated	B:C1112209
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

Clinical	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
composite	O
cure	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
rates	O
across	O
study	O
treatments	I:C3161471
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
complicated	B:C0042029
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

Clinical	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
composite	O
cure	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
rates	O
across	O
study	O
treatments	I:C3161471
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane	B:C3656593
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

Clinical	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
and	O
composite	O
cure	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
rates	O
across	O
study	O
treatments	I:C3161471
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
and	O
active	O
comparator	O
treatment	B:C0087111
groups	O
.	O

However	O
,	O
significantly	O
higher	O
composite	O
cure	O
rates	O
were	O
reported	B:C0700287
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
than	O
with	O
levofloxacin	O
in	O
patients	O
without	O
diabetes	O
with	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
79.5	O
%	O
vs	O
69.9	O
%	O
;	O
P	O
=	O
0.0048	O
)	O
.	O

However	O
,	O
significantly	O
higher	O
composite	O
cure	O
rates	O
were	O
reported	O
with	O
ceftolozane	B:C3656593
/	I:C3656593
tazobactam	I:C3656593
than	O
with	O
levofloxacin	O
in	O
patients	O
without	O
diabetes	O
with	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
79.5	O
%	O
vs	O
69.9	O
%	O
;	O
P	O
=	O
0.0048	O
)	O
.	O

However	O
,	O
significantly	O
higher	O
composite	O
cure	O
rates	O
were	O
reported	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
than	O
with	O
levofloxacin	B:C0282386
in	O
patients	O
without	O
diabetes	O
with	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
79.5	O
%	O
vs	O
69.9	O
%	O
;	O
P	O
=	O
0.0048	O
)	O
.	O

However	O
,	O
significantly	O
higher	O
composite	O
cure	O
rates	O
were	O
reported	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
than	O
with	O
levofloxacin	O
in	O
patients	O
without	O
diabetes	B:C0011847
with	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
79.5	O
%	O
vs	O
69.9	O
%	O
;	O
P	O
=	O
0.0048	O
)	O
.	O

However	O
,	O
significantly	O
higher	O
composite	O
cure	O
rates	O
were	O
reported	O
with	O
ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
than	O
with	O
levofloxacin	O
in	O
patients	O
without	O
diabetes	O
with	O
complicated	B:C0042029
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
(	O
79.5	O
%	O
vs	O
69.9	O
%	O
;	O
P	O
=	O
0.0048	O
)	O
.	O

Significantly	O
higher	O
rates	O
of	O
adverse	B:C0877248
events	I:C0877248
observed	O
in	O
patients	O
with	O
diabetes	O
were	O
likely	O
due	O
to	O
comorbidities	O
because	O
treatment	O
-	O
related	O
adverse	O
events	I:C0877248
were	O
similar	O
between	O
groups	O
.	O

Significantly	O
higher	O
rates	O
of	O
adverse	O
events	I:C0877248
observed	O
in	O
patients	O
with	O
diabetes	B:C0011847
were	O
likely	O
due	O
to	O
comorbidities	O
because	O
treatment	O
-	O
related	O
adverse	O
events	I:C0877248
were	O
similar	O
between	O
groups	O
.	O

Significantly	O
higher	O
rates	O
of	O
adverse	O
events	I:C0877248
observed	O
in	O
patients	O
with	O
diabetes	O
were	O
likely	O
due	O
to	O
comorbidities	O
because	O
treatment	B:C0087111
-	O
related	O
adverse	O
events	I:C0877248
were	O
similar	O
between	O
groups	O
.	O

Significantly	O
higher	O
rates	O
of	O
adverse	O
events	I:C0877248
observed	O
in	O
patients	O
with	O
diabetes	O
were	O
likely	O
due	O
to	O
comorbidities	O
because	O
treatment	O
-	O
related	O
adverse	B:C0877248
events	I:C0877248
were	O
similar	O
between	O
groups	O
.	O

In	O
this	O
post	O
hoc	B:C0936012
analysis	I:C0936012
,	O
patients	O
with	O
diabetes	O
in	O
general	O
were	O
older	O
,	O
heavier	O
,	O
and	O
had	O
a	O
greater	O
number	O
of	O
complicating	O
comorbidities	O
.	O

In	O
this	O
post	O
hoc	O
analysis	I:C0936012
,	O
patients	O
with	O
diabetes	B:C0011847
in	O
general	O
were	O
older	O
,	O
heavier	O
,	O
and	O
had	O
a	O
greater	O
number	O
of	O
complicating	O
comorbidities	O
.	O

In	O
this	O
post	O
hoc	O
analysis	I:C0936012
,	O
patients	O
with	O
diabetes	O
in	O
general	O
were	O
older	B:C0001792
,	O
heavier	O
,	O
and	O
had	O
a	O
greater	O
number	O
of	O
complicating	O
comorbidities	O
.	O

Patients	O
with	O
diabetes	B:C0011847
had	O
lower	O
cure	O
rates	O
and	O
a	O
significantly	O
higher	O
frequency	O
of	O
adverse	O
events	I:C0877248
than	O
patients	O
without	O
diabetes	O
,	O
likely	O
because	O
of	O
the	O
higher	O
rates	O
of	O
medical	O
complications	O
in	O
this	O
subgroup	O
.	O

Patients	O
with	O
diabetes	O
had	O
lower	B:C0441994
cure	O
rates	O
and	O
a	O
significantly	O
higher	O
frequency	O
of	O
adverse	O
events	I:C0877248
than	O
patients	O
without	O
diabetes	O
,	O
likely	O
because	O
of	O
the	O
higher	O
rates	O
of	O
medical	O
complications	O
in	O
this	O
subgroup	O
.	O

Patients	O
with	O
diabetes	O
had	O
lower	O
cure	O
rates	O
and	O
a	O
significantly	O
higher	O
frequency	O
of	O
adverse	B:C0877248
events	I:C0877248
than	O
patients	O
without	O
diabetes	O
,	O
likely	O
because	O
of	O
the	O
higher	O
rates	O
of	O
medical	O
complications	O
in	O
this	O
subgroup	O
.	O

Patients	O
with	O
diabetes	O
had	O
lower	O
cure	O
rates	O
and	O
a	O
significantly	O
higher	O
frequency	O
of	O
adverse	O
events	I:C0877248
than	O
patients	O
without	O
diabetes	B:C0011847
,	O
likely	O
because	O
of	O
the	O
higher	O
rates	O
of	O
medical	O
complications	O
in	O
this	O
subgroup	O
.	O

Ceftolozane	B:C3656593
/	I:C3656593
tazobactam	I:C3656593
was	O
shown	O
to	O
be	O
at	O
least	I:C0441994
as	O
effective	O
as	O
comparators	O
in	O
treating	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
and	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
in	O
this	O
population	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
was	O
shown	O
to	O
be	O
at	B:C0441994
least	I:C0441994
as	O
effective	O
as	O
comparators	O
in	O
treating	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
and	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
in	O
this	O
population	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
was	O
shown	O
to	O
be	O
at	O
least	I:C0441994
as	O
effective	O
as	O
comparators	O
in	O
treating	B:C0087111
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
and	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
in	O
this	O
population	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
was	O
shown	O
to	O
be	O
at	O
least	I:C0441994
as	O
effective	O
as	O
comparators	O
in	O
treating	O
complicated	B:C0042029
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
and	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
in	O
this	O
population	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
was	O
shown	O
to	O
be	O
at	O
least	I:C0441994
as	O
effective	O
as	O
comparators	O
in	O
treating	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
and	O
complicated	B:C1112209
intra-abdominal	I:C1112209
infections	I:C1112209
in	O
this	O
population	O
.	O

Ceftolozane	O
/	I:C3656593
tazobactam	I:C3656593
was	O
shown	O
to	O
be	O
at	O
least	I:C0441994
as	O
effective	O
as	O
comparators	O
in	O
treating	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
and	O
complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
in	O
this	O
population	B:C1257890
.	O

complicated	B:C1112209
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
NCT01445665	O
and	O
NCT01445678	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
September	O
26	O
,	O
2011	O
)	O
;	O
complicated	O
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
NCT01345929	O
and	O
NCT01345955	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
April	O
28	O
,	O
2011	O
)	O
.	O

complicated	O
intra-abdominal	I:C1112209
infections	I:C1112209
,	O
NCT01445665	O
and	O
NCT01445678	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
September	O
26	O
,	O
2011	O
)	O
;	O
complicated	B:C0042029
urinary	I:C0042029
tract	I:C0042029
infections	I:C0042029
,	O
NCT01345929	O
and	O
NCT01345955	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
April	O
28	O
,	O
2011	O
)	O
.	O

